Recent Peer-Reviewed Publication Confirms Patient Satisfaction with Multiple Allergy Immunotherapy Options
17 nov. 2021 09h30 HE
|
Allovate, LLC
New York, Nov. 17, 2021 (GLOBE NEWSWIRE) -- A recent article in the peer-reviewed journal International Forum of Allergy and Rhinology reported the results of a survey offered to individuals with...
Allovate Therapeutics Extends Free Allerdent® Program
23 juil. 2020 15h37 HE
|
Allovate, LLC
New York, July 23, 2020 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a New York-based biotechnology company, announced today that it has extended its free Allerdent® program. Allerdent® is a...
Allovate Therapeutics Provides Free Allerdent® To Physicians
06 mai 2020 09h05 HE
|
Allovate, LLC
New York, May 06, 2020 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available...
Allovate Therapeutics Appoints Bob Pomrenke as CEO
02 avr. 2019 14h04 HE
|
Allovate, LLC
New York, April 02, 2019 (GLOBE NEWSWIRE) -- Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the...
Allovate Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy Platform
08 mars 2019 10h01 HE
|
Allovate, LLC
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce that the...
Allovate Therapeutics Announces Issuance of Second Japanese Patent, Expanding Global Coverage of the Oral Mucosal Immunotherapy Platform
21 mars 2018 08h37 HE
|
Allovate, LLC
New York, March 21, 2018 (GLOBE NEWSWIRE) --
Allovate Therapeutics, a biopharmaceutical company focused on improving treatment options for allergies, announced today that the...
New “Test and Treatment” Allergy Program Enables All Physicians To Provide Convenient And Effective Allergy Care
19 déc. 2017 08h17 HE
|
Allovate, LLC
New York City, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Pediatric Allergy Solutions (“PAS”) and Allovate Therapeutics (“Allovate®”) announce that they have signed an exclusive agreement to combine PAS’s...
Allovate Therapeutics Announces Positive Results of Proof-of-Concept Study of Oral Mucosal Immunotherapy (OMIT)
25 avr. 2016 09h00 HE
|
Allovate, LLC
Oral mucosal route of administration efficacious for allergy immunotherapy Patient-friendly toothpaste fits into everyday routine No gastrointestinal side effects observed with OMIT Indications...
Allovate Therapeutics Announces Issuance of U.S. Patent Covering Novel Oral Mucosal Immunotherapy Platform
29 févr. 2016 07h15 HE
|
Allovate, LLC
New York, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a biopharmaceutical company focused on improving treatment for allergies, announced today that the U.S Patent and Trademark...
Results of Oral Mucosal Immunotherapy (OMIT) Study to be Presented at American Academy of Otolaryngic Allergy (AAOA) 2015 Annual Scientific Meeting
16 sept. 2015 13h44 HE
|
Allovate, LLC
New York, Sept. 16, 2015 (GLOBE NEWSWIRE) -- Allovate, LLC, a specialty biopharmaceutical company focused on improving treatment for allergies, announced today that results of a clinical trial of oral...